ATEM Capital

ATEM Capital is an investment firm that strategically deploys capital into innovations across the life sciences industry, specifically targeting biotechnologies with the potential to cure diseases and extend human lifespan. The firm identifies breakthroughs characterized by unmet clinical needs, robust intellectual property protection, and a clear appeal to larger strategic players. They work in close partnership with leading venture capital groups throughout the United States and Europe to foster development within their portfolio.

Founded in 2014, the firm's inception was driven by a clear recognition of the consistent growth and investment opportunities within the global healthcare market. This insight centered on the rising public and private spending in healthcare, fueled by factors like population aging, creating a fertile ground for high-impact investments in novel therapies and medical advancements. This strategic approach underpins their focus on disruptive technologies.

The firm's portfolio comprises companies developing treatments across diverse areas, including rare endocrine diseases, oncology, kidney diseases, and genetic therapies. ATEM Capital's overarching vision is to support the development of life-changing treatments, contributing to human health by addressing critical medical challenges. They aim to leverage the steady expansion of the life sciences sector to back innovations that define the future of medicine.